Related Experiment Videos
Antiplatelet therapy in the prevention of cardiovascular diseases
P M Mannucci1, C Cimminiello, M Cattaneo
1Centro Emofilia e Trombosi, Angelo Bianchi Bonomi, IRCCS, Ospedale Maggiore e Universita degli Studi di Milano.
Insights
Acetylsalicylic acid (ASA) and ticlopidine are effective antiplatelet agents for preventing ischemic cardiovascular events. Their roles vary, with limited use in primary cardiovascular disease prevention.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Platelet-rich thrombi are implicated in ischemic cardiovascular events.
- Antiplatelet agents are crucial in managing conditions associated with platelet aggregation.
Purpose of the Study:
- To review the efficacy of antiplatelet agents in preventing ischemic cardiovascular events.
- To compare the roles of acetylsalicylic acid (ASA) and ticlopidine in various cardiovascular conditions.
Main Methods:
- Review of clinical trials and existing literature on antiplatelet therapy.
- Analysis of agent efficacy in acute myocardial infarction, unstable angina, stroke, and peripheral ischemia.
Main Results:
- Acetylsalicylic acid (ASA) is effective in acute myocardial infarction, post-infarction, and transient ischemic attacks.
- ASA also prevents cardiovascular events and reduces bypass graft occlusion but not anginal attacks.
- Ticlopidine is a primary treatment for major stroke and peripheral vascular ischemia, and an alternative for transient ischemic attacks and unstable angina.
Conclusions:
- Antiplatelet agents like ASA and ticlopidine play significant roles in secondary cardiovascular event prevention.
- Current evidence suggests a limited role for antiplatelet agents in the primary prevention of cardiovascular disease.
Abstract:
Antiplatelet agents have been studied in a number of clinical trials to evaluate their efficacy in the prevention of ischemic cardiovascular events related to platelet-rich thrombi. Acetylsalicylic acid (ASA) is definitely effective in the hospital phase of acute myocardial infarction; it also prevents cardiovascular events but not anginal attacks in patients with unstable angina and reduces the rate of occlusion of coronary artery bypass grafts. ASA is often used in the post-infarction period, even though anticoagulant therapy is probably more effective; it is also effective in patients with transient ischemic attacks in the brain. Ticlopidine is the treatment of choice in patients with major stroke and in those with peripheral vascular ischemia; it can also be considered a valid alternative to ASA in the management of transient ischemic attacks and unstable angina. There is at the moment little role for antiplatelet agents in the primary prevention of cardiovascular disease.